P3 Health Partners Inc (PIII)
0.6069
+0.01
(+1.13%)
USD |
NASDAQ |
May 17, 16:00
0.6069
0.00 (0.00%)
After-Hours: 20:00
P3 Health Partners SG&A Expense (Quarterly): 27.72M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 27.72M |
| December 31, 2023 | 25.15M |
| September 30, 2023 | 33.72M |
| June 30, 2023 | 28.08M |
| March 31, 2023 | 38.64M |
| December 31, 2022 | 41.43M |
| September 30, 2022 | 38.98M |
| Date | Value |
|---|---|
| June 30, 2022 | 42.51M |
| March 31, 2022 | 39.46M |
| September 30, 2021 | 20.92M |
| June 30, 2021 | 18.75M |
| March 31, 2021 | 15.33M |
| June 30, 2020 | 11.92M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
11.92M
Minimum
Jun 2020
42.51M
Maximum
Jun 2022
29.43M
Average
28.08M
Median
Jun 2023
SG&A Expense (Quarterly) Benchmarks
| American Shared Hospital Services | 1.76M |
| Novo Integrated Sciences Inc | 2.864M |
| Astrana Health Inc | 38.72M |
| Cryo-Cell International Inc | 4.340M |
| Biote Corp | 23.01M |